Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Xbrane Biopharma AB
- Study ID
- NCT03805100
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ranibizumab — BIOLOGICALIntravitreal injection
Study Details
The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).
Key Dates
- First listed
- Jan 15, 2019
- Start date
- Apr 19, 2019
- Status verified
- Feb 2023
- Primary completion
- May 11, 2021
- Completion
- Nov 11, 2021
Study Design
- Enrollment
- 582 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: XlucaneXlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
- Active Comparator: LucentisLucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
Primary Outcome Measure
Change in Best Corrected Visual Acuity (BCVA) [ Time Frame: Baseline and Week 8 ]
Locations (26)
Find similar trials in Gilbert, AZ
By condition
By specialty
Related Studies
- Stem Cell Ophthalmology Treatment Study IIRecruiting · MD Stem Cells · Westport, Connecticut
- NYSCF Scientific Discovery BiobankRecruiting · New York Stem Cell Foundation Research Institute · New York, New York
- Quest to Analyze One Thousand Humans MeditatingEnrolling By Invitation · Tobias Moeller-Bertram · Palm Desert, California
- A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)PHASE2 · Recruiting · Janssen Research & Development, LLC · Tucson, Arizona